Neurocrine Biosciences Reports New INGREZZA Data in Tardive Dyskinesia
SAN DIEGO, June 8, 2026 Neurocrine Biosciences announced new clinical findings demonstrating the long-term effectiveness of INGREZZA® (valbenazine) capsules...
tardive dyskinesia
Advertisement
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Teva Presents New AUSTEDO Data Supporting Sustained TD Treatment
PARSIPPANY, New Jersey, USA & TEL AVIV, Israel – June 8, 2026 Teva Pharmaceuticals has unveiled new real-world and...
Teva Uncovers Widespread Underdiagnosis of Tardive Dyskinesia in Young Patients
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD...
Neurocrine Defines TDIS Threshold for TD Treatment Impact
SAN DIEGO, California, April 29, 2026 Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of...
Advertisements
Revolution Medicines Reports Phase 3 Survival Gain PDAC
REDWOOD CITY, CALIFORNIA, USA, April 13, 2026 Revolution Medicines has announced positive topline results from its pivotal Phase 3...
Neurocrine Shows INGREZZA Persistence Edge in TD Study
SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...
Advertisement
